Sponsor Overview
Explore verified public information about Baylor College of Medicine's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 4 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Compassionate Use/EA IND (Expanded Access for an Investigational New Drug) EIND: For emergency use when a patient must be treated prior to a formal written submission to the FDA.”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 1 supporting sources.
Conditions: Cholestasis, Growth Failure
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 2 supporting sources.
Conditions: Hyperinsulinemic Hypoglycemia, Persistent, Congenital Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Conditions: EBV Infection, CMV Infection, Adenoviral Infection
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.